XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies

Written By Meghan Ferrall-Fairbanks

Kruer TL, Quintana A, Newman H, Ferrall-Fairbanks MC, Zhang L, McLemore A, Neupane S, Yang Q, Dankyi NA, Balasis ME, Letson C, Komrokji R, Chaudhry S, Totiger TM, Traia J, Figueroa ME, Ryder CB, Cluzeau T, Taylor J, Sallman DA, and Padron E. “XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.” Blood. 2025 Oct 30. Vol. 146, No. 18

doi: 10.1182/blood.2025028803 PMID: 40737597

Meghan Ferrall-Fairbanks
Next

RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis